natgillin/translations-raw huggingface dataset:
For the treatment of bovine respiratory diseases several appropriate clinical studies from 1988 and 1989 using the dose regime of 100 000 IU/kg body weight once or twice in 48 hours interval, have been presented. 
Za zdravljenje bolezni dihal pri govedu je bilo predloženih več ustreznih kliničnih študij iz leta 1988 in 1989, v katerih so uporabili režim odmerjanja 100.000 i.e./kg telesne mase enkrat ali dvakrat v razmiku 48 ur.
Scientific conclusions and grounds for amendment of the summaries of product characteristics, labelling and package leaflets 
Znanstveni zaključki in podlaga za spremembo povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo
The pharmacokinetic characteristics derived from this study demonstrate that in plasma relatively low spiramycin levels (Cmax: 1.44 IU/ml corresponding to 0.45 µg/ml) were reached with the treatment regime, whereas considerably higher spiramycin levels were reached in milk (50-fold of the plasma levels). 
Farmakokinetične lastnosti, ki izhajajo iz te študije, kažejo, da se s tem režimom zdravljenja dosežejo relativno majhne koncentracije spiramicina v plazmi (Cmax: 1,44 i.e./ml, kar ustreza 0,45 µg/ml), znatno večje pa v mleku (50-krat večje od koncentracij v plazmi).
By using the pharmacodynamic and pharmacokinetic data mentioned above, a detailed PK/PDassessment was performed, which was based on two parameters: the T>MIC, which is recommended for time-dependent antibiotics like the macrolides, and the AUC/MIC, which is recommended for specific macrolides like azithromycin. 
Na podlagi zgoraj omenjenih farmakodinamičnih in farmakokinetičnih podatkov je bila opravljena podrobna ocena farmakodinamike/farmakokinetike, ki je temeljila na dveh parametrih: T>MIK, ki se priporoča za časovno odvisne antibiotike, kot so makrolidi, in AUC/MIK, ki se priporoča za specifične makrolide, kot je azitromicin.
Only acute cases of mastitis caused by S. aureus with clinical signs observed for less than 24 h should be treated. 
Zdravijo se lahko samo akutni primeri mastitisa, ki ga povzroča bakterija S. aureus, pri katerih se klinični znaki pojavijo za manj kot 24 ur.
The maximal volume to be injected is 20 ml per injection site as this was the maximal volume administered at the residue depletion study. 
Največja količina zdravila, ki se lahko injicira na eno mesto, je 20 ml, saj je bila to največja količina, ki so jo injicirali v študiji o izločanju ostankov.
In sows has been authoresed for the treatment of mastitis at 75 000 IU/kg once or twice in 24 hour interval. 
Pri svinjah pa je odobreno za zdravljenje mastitisa v odmerku 75.000 i.e./kg enkrat ali dvakrat v razmiku 24 ur.
One study was conducted at the recommended dose of 100 000 IU/kg body weight twice at 48 hours of interval, which showed that the injection site muscle residues were still above the maximum residue limit for muscle (200 μg/kg) at Day 49 post-treatment. 
Izvedena je bila ena študija z uporabo priporočenega odmerka 100.000 i.e./kg telesne mase dvakrat v razmiku 48 ur, ki je pokazala, da so bili 49 dni po zdravljenju ostanki na mestu injiciranja v mišico še vedno nad mejno vrednostjo ostankov za mišico (200 μg/kg).
Spiramycin is eliminated primarily by biliary excretion. 
Spiramicin se izloča predvsem z žolčem.
Using the statistical analysis1 the residues depletion at the injection sites suggested a withdrawal period of 52 days. 
Statistična analiza1 je pokazala, da bi morala biti karenca glede na izločanje ostankov z mest injiciranja 52 dni.
• on the basis of the available residue depletion data in cattle, the CVMP considered that withdrawal periods should be amended to provide assurance for consumer safety; 
• odbor CVMP je menil, da je treba na podlagi razpoložljivih podatkov o izločanju ostankov pri govedu spremeniti karence, tako da se zagotovi varnost potrošnikov;
Cattle (calves) 
Govedo (teleta)
The pharmacokinetic characteristics derived from specific studies demonstrated that in plasma relatively low spiramycin levels (Cmax: 6-10 IU/ml corresponding to 2-3 µg/ml) were reached with the treatment regime, whereas considerably higher spiramycin levels were reached in bronchoalveolar lavage (4-5-fold of the plasma levels) and in lung tissue (100-fold of the plasma levels). 
Farmakokinetične lastnosti, ugotovljene v posebnih študijah, so pokazale, da se s tem režimom zdravljenja dosežejo relativno majhne koncentracije spiramicina v plazmi (Cmax: 6-10 i.e./ml, kar ustreza 2-3 µg/ml), znatno večje pa v bronhoalveolarnem izpirku (4- do 5-krat večje od koncentracij v plazmi) in pljučnem tkivu (100-krat večje od koncentracij v plazmi).
Residue depletion studies performed at the dose of 100 000 IU/kg body weight, intramuscularly at 48 hours interval, were available in adult cattle. 
Študije o izločanju ostankov, izvedene z uporabo odmerka 100.000 i.e./kg telesne mase intramuskularno v razmiku 48 ur, so bile na voljo za odraslo govedo.
Spiramycin is active against Staphylococcus aureus, Mannheimia haemolytica and Pasteurella multocida. 
Spiramicin deluje proti bakterijam Staphylococcus aureus, Mannheimia haemolytica in Pasteurella multocida.
The veterinary medicinal product Suanovil 20 and its associated names has been authorised by several Member States for use in cattle for the treatment and prevention of respiratory infections and gastrointestinal infections, mastitis, metritis, omphalitis and omphalophlebitis, arthritis and interdigital abscesses at a dose of 30 000 IU/kg body weight once or twice in 24 hour interval for adult cattle and at 75 000 IU/kg body weight once or twice in 24 hour interval for calves. 
Zdravilo za uporabo v veterinarski medicini Suanovil 20 in povezana imena so odobrena v več državah članicah za uporabo pri govedu za zdravljenje in preprečevanje okužb dihal in okužb prebavil, mastitisa, metritisa, omfalitisa in omfaloflebitisa, artritisa ter interdigitalnih abscesov v odmerku 30.000 i.e./kg telesne mase enkrat ali dvakrat v razmiku 24 ur za odraslo govedo in v odmerku 75.000 i.e./kg telesne mase enkrat ali dvakrat v razmiku 24 ur za teleta.
Treatment of acute clinical mastitis in lactating cows caused by Staphylococcus aureus strains sensitive to spiramycin. 
Zdravljenje akutnega kliničnega mastitisa pri kravah v obdobju laktacije, ki ga povzročajo sevi bakterije Staphylococcus aureus, občutljivi za spiramicin.
The indication was substantiated by in vitro susceptibility data for Pasteurella multocida and Mannheimia haemolytica and by pharmacokinetic data of spiramycin in the target species, on the basis of which a detailed pharmacokinetic/pharmacodynamic (PK/PD) assessment has been performed. 
Indikacijo podpirajo podatki o občutljivosti in vitro za bakteriji Pasteurella multocida in Mannheimia haemolytica ter farmakokinetični podatki o spiramicinu pri ciljnih živalskih vrstah, na podlagi katerih je bila opravljena podrobna ocena farmakokinetike/farmakodinamike (FK/FD).
Delete, target species pigs and any information related to these species from the product information. 
Iz informacij o zdravilu izbrišite ciljno živalsko vrsto prašiče in vse informacije, povezane s to živalsko vrsto.
By using the pharmacodynamic and pharmacokinetic data mentioned abobe, a detailed PK/PD assessment was performed, which was based on two parameters: the T>MIC (time during which the concentration exceeds the MIC), which is recommended for time-dependent antibiotics like the macrolides, and the AUC/MIC (area under the curve to MIC), which is recommended for specific macrolides like azithromycin. 
Na podlagi zgoraj omenjenih farmakodinamičnih in farmakokinetičnih podatkov je bila opravljena podrobna ocena farmakodinamike/farmakokinetike, ki je temeljila na dveh parametrih: T>MIK (čas, ko je koncentracija večja od MIK), ki se priporoča za časovno odvisne antibiotike, kot so makrolidi, in AUC/MIK (razmerje med površino pod krivuljo in MIK), ki se priporoča za specifične makrolide, kot je azitromicin.
In pigs, the products has been authoresed for the treatment of respiratory infections, pig house cough, atrophic rhinitis, infections caused by Streptococcus spp., erysipelas, arthritis, treatment and prevention of mastitis, prevention of neonatal infections in piglets and infectious gastro-enteritis at 75 000 IU/kg body weight once or twice in 24 hour interval. 
Pri prašičih je zdravilo odobreno za zdravljenje okužb dihal, prašičjega kašlja, atrofičnega rinitisa, okužb, ki jih povzročajo bakterije Streptococcus spp., prašičje rdečice in artritisa, za zdravljenje in preprečevanje mastitisa ter preprečevanje neonatalnih okužb pri prašičkih in nalezljivega gastroenteritisa v odmerku 75.000 i.e./kg telesne mase enkrat ali dvakrat v razmiku 24 ur.
Using the statistical analysis the calculated withdrawal period for cattle meat and offal is 75 days. 
Karenca za goveje meso in organe, ki so jo izračunali s statistično analizo, je 75 dni.
As no residue depletion study was provided following administration of 100 000 IU/kg intramuscularly twice with 48 hours of interval, no withdrawal period for milk is recommended for this dosage regimen. 
Študija o izločanju ostankov po odmerjanju 100.000 i.e./kg intramuskularno dvakrat v razmiku 48 ur ni bila predložena, zato za ta režim odmerjanja ni priporočena nobena karenca za mleko.
It should be noted that the generic product, Spirovet, has been authorised in several Member States for a restricted list of indications, only i.e. in adult cattle for the treatment of respiratory diseases, mastitis, metritis and interdigital necrobacillosis at a dose of 30 000 IU/kg once or twice in 24 hour interval. 
Omeniti je treba, da je generično zdravilo Spirovet v več državah članicah odobreno za manj indikacij, in sicer je pri odraslem govedu odobreno samo za zdravljenje bolezni dihal, mastitisa, metritisa in interdigitalne nekrobaciloze v odmerku 30.000 i.e./kg enkrat ali dvakrat v razmiku 24 ur.
Insufficient data or no data at all are available for all other indications and dosage regimens in cattle (i.e. metritis, enteric infections, omphalitis, omphalophlebitis, arthritis, interdigital abscesses) and all indications in pigs. 
Podatki za vse ostale indikacije (to so metritis, črevesne okužbe, omfalitis, omfaloflebitis, artritis in interdigitalni abscesi) in režime odmerjanja pri govedu ter za vse indikacije pri prašičih so nezadostni ali sploh niso na voljo.
29 avenue Tony Garnier 69007- Lyon France 
29 avenue Tony Garnier 69007- Lyon Francija
Overall, the benefit-risk balance of all concerned products is considered positive provided their use will be limited to the treatment of bovine respiratory infections caused by susceptible strains of Pasteurella multocida and Mannheimia haemolytica at a dose of 100 000 IU/kg administered intramuscularly twice at 48 hours of interval. 
Na splošno je razmerje med tveganji in koristmi za vsa zadevna zdravila pozitivno pod pogojem, da se njihova uporaba omeji na zdravljenje okužb dihal pri govedu, ki jih povzročajo občutljivi sevi bakterij Pasteurella multocida in Mannheimia haemolytica, v odmerku 100.000 i.e./kg, ki se daje intramuskularno dvakrat v razmiku 48 ur.
C. For Captalin and its associated names listed in Annex I containing 1 000 000 IU spiramycin per ml 
C. Za zdravilo Captalin in povezana imena, navedena v Prilogi I, ki vsebujejo 1.000.000 i.e. spiramicina na ml
Data from clinical surveillance monitoring programs (VetPath I: 1997-2004, VetPath III: 2007-2012) show that a considerable proportion of bovine mastitis strains of S. aureus were susceptible to spiramycin in vitro, with MIC50 and MIC90 of 4 µg/ml and 8 µg/ml, respectively. 
2007-2012) kažejo, da je bil znaten delež sevov bakterije S. aureus, ki povzročajo mastitis pri govedu, in vitro občutljiv za spiramicin, pri čemer sta MIK50 oziroma MIK90 znašali 4 µg/ml oziroma 8 µg/ml.
Therefore Spirovet should not be used for treatment of respiratory infections in animals producing milk for human consumption. 
Zaradi tega se zdravilo Spirovet ne sme uporabljati za zdravljenje okužb dihal pri živalih, katerih mleko je namenjeno prehrani ljudi.
4.2 Indications for use, specifying the target species Treatment of respiratory infections caused by Pasteurella multocida and Mannheimia haemolytica. 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Zdravljenje okužb dihal, ki jih povzročata bakteriji Pasteurella multocida in Mannheimia haemolytica.
When applying these concepts it has been concluded that based on PK/PD-considerations in cattle, following 2 injections at 100 000 IU/kg body weight at 48 hours interval, the spiramycin concentrations in lung, macrophages and bronchoalveolar lavage reached the respiratory pathogens with MICs up to 128 µg/ml. 
Ob upoštevanju teh konceptov je bilo zaključeno, da je glede na farmakokinetiko/farmakodinamiko pri govedu koncentracija spiramicina v pljučih, makrofagih in bronhoalveolarnem izpirku po 2 injiciranjih 100.000 i.e./kg telesne mase v razmiku 48 ur dosegla respiratorne patogene z minimalnimi inhibitornimi koncentracijami do 128 µg/ml.
Thus a 62 days withdrawal period for meat and offal is recommended. 
Tako je priporočena karenca za meso in organe 62 dni.
The benefit-risk balance of Suanovil 20 and Spirovet is considered positive provided that their use in the treatment of mastitis will be limited to treatment of acute bovine S. aureus-mastitis caused by susceptible strains at a dose of 30 000 IU/kg administered intramuscularly twice at 24 hours of interval. 
Razmerje med tveganji in koristmi za zdravili Suanovil 20 in Spirovet je pozitivno pod pogojem, da se njuna uporaba pri zdravljenju mastitisa omeji na zdravljenje akutnega mastitisa pri govedu, ki ga povzročajo občutljivi sevi bakterije S. aureus, v odmerku 30.000 i.e./kg, ki se daje intramuskularno dvakrat v razmiku 24 ur.
Spiramycin is a macrolide antibiotic exerting bacteriostatic action against Mycoplasma, Gram-negative and Gram-positive bacteria which cause infections in cattle and pigs. 
Spiramicin je makrolidni antibiotik, ki deluje bakteriostatično proti mikoplazmam ter gramnegativnim in grampozitivnim bakterijam, ki povzročajo okužbe pri govedu in prašičih.
Captalin solution for injection has been authorised by severeal Member States for use in cattle for the treatment of respiratory diseases at a dose of 100 000 IU/kg body weight twice at 48 hour interval and for the metaphylaxis of respiratrory diseases at a single dose of 100 000 IU/kg body weight. 
Zdravilo Captalin raztopina za injiciranje je odobreno v več državah članicah za uporabo pri govedu za zdravljenje bolezni dihal v odmerku 100.000 i.e./kg telesne mase dvakrat v razmiku 48 ur ter za metafilakso bolezni dihal v enkratnem odmerku 100.000 i.e./kg telesne mase.
Grounds for amendment of the summaries of product characteristics, labelling and package leaflets 
Podlaga za spremembo povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo
Treatment of respiratory infections caused by Pasteurella multocida and Mannheimia haemolytica at a dose regime of 100 000 IU/kg body weight twice at 48 hours of interval. 
Zdravljenje okužb dihal, ki jih povzročata bakteriji Pasteurella multocida in Mannheimia haemolytica, v odmerku 100.000 i.e./kg telesne mase dvakrat v razmiku 48 ur.
A. For Suanovil 20 and its associated names listed in Annex I containing 600 000 IU spiramycin per ml 
A. Za zdravilo Suanovil 20 in povezana imena, navedena v Prilogi I, ki vsebujejo 600.000 i.e. spiramicina na ml
Do not administer more than 15 ml per injection site. 
Na eno mesto lahko injicirate največ 15 ml zdravila.
Mastitis: 30 000 IU of spiramycin per kg body weight (i.e. 5 ml of product per 100 kg body weight) twice at 24 h of interval. 
Mastitis: 30.000 i.e. spiramicina na kg telesne mase (tj. 5 ml zdravila na 100 kg telesne mase) dvakrat v razmiku 24 ur.
The indication was substantiated by in vitro susceptibility data for Staphylococcus aureus strains and by PK data of spiramycin in the target species, on the basis of which a detailed PK/PD assessment has been performed. 
Indikacijo podpirajo podatki o občutljivosti in vitro za seve bakterije Staphylococcus aureus ter farmakokinetični podatki o spiramicinu pri ciljnih živalskih vrstah, na podlagi katerih je bila opravljena podrobna ocena farmakokinetike/farmakodinamike.
B. For Spirovet and its associated names listed in Annex I containing 600 000 IU spiramycin per ml 
B. Za zdravilo Spirovet in povezana imena, navedena v Prilogi I, ki vsebujejo 600.000 i.e. spiramicina na ml
Do not administer more than 20 ml per injection site. 
Na eno mesto lahko injicirate največ 20 ml zdravila.
Treatment of respiratory infections caused by Pasteurella multocida and Mannheimia haemolytica. 
Zdravljenje okužb dihal, ki jih povzročata bakteriji Pasteurella multocida in Mannheimia haemolytica.
INDICATIONS Treatment of respiratory infections caused by Pasteurella multocida and Mannheimia haemolytica. 
INDIKACIJE Zdravljenje okužb dihal, ki jih povzročata bakteriji Pasteurella multocida in Mannheimia haemolytica.
Lactating cows 
Krave v obdobju laktacije
The recommended dose for acute clinical mastitis in lactating cows caused by Staphylococcus aureus strains susceptible to spiramycin is 30 000 IU/kg body weight, intramuscularly twice at 24 hours of interval. 
Priporočeni odmerek za akutni klinični mastitis pri kravah v obdobju laktacije, ki ga povzročajo sevi bakterije Staphylococcus aureus, občutljivi za spiramicin, je 30.000 i.e./kg telesne mase intramuskularno dvakrat v razmiku 24 ur.
100 000 IU of spiramycin per kg body weight (i.e. 1 ml of product per 10 kg body weight) twice at 48 h of interval. 
100.000 i.e. spiramicina na kg telesne mase (tj. 1 ml zdravila na 10 kg telesne mase) dvakrat v razmiku 48 ur.
Treatment of acute clinical mastitis in lactating cows caused by Staphylococcus aureus strains sensitive to spiramycin at a dose regime of 30 000 IU/kg body weight twice at 24 hours of interval. 
Zdravljenje akutnega kliničnega mastitisa pri kravah v obdobju laktacije, ki ga povzročajo sevi bakterije Staphylococcus aureus, občutljivi za spiramicin, v odmerku 30.000 i.e./kg telesne mase dvakrat v razmiku 24 ur.
Respiratory infections: 100 000 IU of spiramycin per kg body weight (i.e. 5 ml of product per 30 kg body weight) twice at 48 h of interval. 
Okužbe dihal: 100.000 i.e. spiramicina na kg telesne mase (tj. 5 ml zdravila na 30 kg telesne mase) dvakrat v razmiku 48 ur.
Although results from different laboratories can be compared only with reservation because of the different methods used, Minimum Inhibitory Concentrations (MIC) of spiramycin for the relevant respiratory tract pathogens such as Pasteurella and Mannheimia spp. 
Čeprav je rezultate iz različnih laboratorijev zaradi različnih uporabljenih metod treba primerjati s pridržkom, so bile minimalne inhibitorne koncentracije (MIK) spiramicina za zadevne respiratorne patogene, kot sta bakteriji Pasteurella in Mannheimia spp., običajno porazdeljene v unimodalnem vzorcu na desni strani krivulje porazdelitve MIK, pri čemer so bile vrednosti MIK90 za patogene, izolirane iz goveda, približno 64 µg/ml, kar kaže na omejeno občutljivost teh bakterij za spiramicin in vitro.
No residue depletion study in milk was provided, hence no withdrawal period for milk is recommended. 
Študije o izločanju ostankov iz mleka niso bile predložene, zato priporočila za karenco za mleko ni. Zaradi tega se zdravilo Captalin ne sme uporabljati pri živalih, katerih mleko je namenjeno prehrani ljudi.
Amendments in the relevant sections of the summaries of product characteristics, labelling and package leaflets 
Dopolnila zadevnih poglavij povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo
Further to the efficacy assessment the recommended dose for respiratory infections in cattle is 100 000 IU/kg body weight intramuscularly twice at 48 hours of interval. 
Na podlagi ocene učinkovitosti je priporočeni odmerek za okužbe dihal pri govedu 100.000 i.e./kg telesne mase intramuskularno dvakrat v razmiku 48 ur.
Spiramycin is an antibiotic exerting bacteriostatic action against Mycoplasma, Gram-negative and Gram-positive bacteria. 
Spiramicin je antibiotik, ki deluje bakteriostatično proti mikoplazmam ter gramnegativnim in grampozitivnim bakterijam.
The recommended dose for respiratory infections in cattle is 100 000 IU/kg body weight, intramuscularly twice at 48 hours of interval. 
Priporočeni odmerek za okužbe dihal pri govedu je 100.000 i.e./kg telesne mase intramuskularno dvakrat v razmiku 48 ur.
No residue depletion data in milk was provided following the admistration of Spirovet at the dose of 30 000 IU/per kg body weight, intramuscularly twice at 24 hours of interval. 
Podatki o izločanju ostankov iz mleka po uporabi zdravila Spirovet v odmerku 30.000 i.e./kg telesne mase intramuskularno dvakrat v razmiku 24 ur niso bili predloženi.
This withdrawal period is valid for Suanovil 20 administered at the dose of 30 000 IU/per kg body weight, intramuscularly twice at 24 hours of interval. 
Karenca velja za zdravilo Suanovil 20, ki se daje v odmerku 30.000 i.e./kg telesne mase intramuskularno dvakrat v razmiku 24 ur.
Spiramycin is an antimicrobial exerting bacteriostatic action against Mycoplasma, Gram-negative and Gram-positive bacteria. 
Spiramicin je protimikrobna učinkovina, ki deluje bakteriostatično proti mikoplazmam ter gramnegativnim in grampozitivnim bakterijam.
This withdrawal period is valid after administration of 100 000 IU/kg body weight twice at 48 hours of interval. 
Karenca velja po odmerjanju 100.000 i.e./kg telesne mase dvakrat v razmiku 48 ur.
This withdrawal period is valid for Spirovet administered at the dose of 30 000 IU/per kg body weight, intramuscularly twice at 24 hours of interval. 
Karenca velja za zdravilo Spirovet, ki se daje v odmerku 30.000 i.e./kg telesne mase intramuskularno dvakrat v razmiku 24 ur.
1/1 M 
1/2 Z
Strength Pharmaceutical Form 
Farmacevt ska oblika
Further information on Rixathon can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Rixathon. 
Nadaljnje informacije za zdravilo Rixathon so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Rixathon.
Rixathon received a marketing authorisation valid throughout the EU on 15 June 2017. 
Za zdravilo Rixathon je bilo 15. junija 2017 izdano dovoljenje za promet, veljavno po vsej EU.
These patients are also to receive an alert card, which they are to carry at all times, instructing them to contact their doctor immediately if they have symptoms of infection. 
Ti bolniki morajo prejeti tudi opozorilno kartico, ki jo morajo imeti stalno pri sebi in na kateri je navedeno, da se morajo takoj posvetovati z zdravnikom, če imajo simptome okužbe.
This means that Rixathon is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU. 
To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
The cancer improved in just over 87% of those given Rixathon (271 of 311 patients), and in similar numbers of those given MabThera (274 of 313 patients). 
Rak se je odzval na zdravljenje pri nekaj več kot 87 % (271 od 311) bolnikov, ki so prejemali zdravilo Rixathon, in pri podobnem številu bolnikov, ki so prejemali zdravilo MabThera (274 od 313 bolnikov).
What measures are being taken to ensure the safe and effective use of Rixathon? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rixathon?
It should be given under the close supervision of an experienced healthcare professional and in a place where facilities for resuscitating patients are immediately available. 
Daje se lahko samo pod skrbnim nadzorom izkušenega zdravnika in v ustanovi, kjer so nemudoma na voljo vsi pripomočki za oživljanje.
Before each infusion, the patient should be given an antihistamine (to prevent allergic reactions) and an antipyretic (a medicine to reduce fever). 
Pred vsakim infundiranjem je treba bolniku dati antihistaminik (za preprečitev alergijskih reakcij) in antipiretik (zdravilo za znižanje povišane telesne temperature).
Depending on the condition being treated, the patients are also given other medicines to manage side effects. 
Glede na zdravljeno bolezen bolnik prejme tudi druga zdravila, ki pomagajo obvladati neželene učinke.